Skip to main content
Home
Zeitschriften
Zeitungen
Podcast
Gesundheitspolitik
Praxis
Allerlei
Jobs
Fachgebiete
Allgemeinmedizin Anästhesiologie & Intensivmedizin Apotheke Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kinder & Jugendheilkunde Neurologie & Psychiatrie Orthopädie & Unfallchirurgie Pflege Urologie Zahnmedizin
Subfächer Innere Medizin
Diabetologie Gastroenterologie Infektiologie Kardiologie Onkologie und Hämatologie Pneumologie Rheumatologie
Fortbildungen
Überblick Fortbildungen DFP-Literaturstudium-Artikel DFP-Webcast Fortbildungen DFP-Podcasts
Erweiterte Suche
Anmelden
nach oben
memo - Magazine of European Medical Oncology
Erschienen in:

01.12.2020 | editorial

Treating head and neck cancer—A multidisciplinary effort

verfasst von: Gabriele Gamerith, MD, Assoc. Prof. PD Dr. Thorsten Fuereder

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 4/2020

Einloggen, um Zugang zu erhalten

Auszug

Head and neck (HNC) is the tenth most common cancer worldwide with over 650,000 new cases per year [1‐3]. The major risk factors for development of squamous cell HNC comprise alcohol and tobacco consumption [4]. During the last few decades human papilloma virus (HPV) infection has been identified to contribute to the development of oropharyngeal HNC in a younger subgroup of patients [5]. This population shows a more favorable prognosis compared to HPV-negative disease [5]. Standard treatment options for HNC independent of HPV status include surgery, standard radiation, chemo- or bioradiation and chemotherapy. …
Vorheriger Artikel Homologous recombination deficiency: New biomarkers in innovative treatments
Nächster Artikel Fertility preservation
Literatur
1.
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.CrossRef
2.
Marur S, Forastiere AA. Head and neck cancer: changing epidemiology, diagnosis, and treatment. Mayo Clin Proc. 2008;83:489–501.CrossRef
3.
Pfister DG, Ang KK, Brizel DM, et al. Head and neck cancers, version 2.2013. Featured updates to the NCCN guidelines. J Natl Compr Canc Netw. 2013;11:917–23.CrossRef
4.
World Health Organization, International Agency for Research on Cancer. Alcohol consumption and ethyl carbamate. IARC monographs on the evaluation of carcinogenic risks to humans, Vol. 96. 2010. pp. 3–1383.
5.
Tornesello ML, Perri F, Buonaguro L, Ionna F, Buonaguro FM, Caponigro F. HPV-related oropharyngeal cancers: from pathogenesis to new therapeutic approaches. Cancer Lett. 2014;351:198–205.CrossRef
6.
Leemans CR, Tiwari R, Nauta JJ, van der Waal I, Snow GB. Recurrence at the primary site in head and neck cancer and the significance of neck lymph node metastases as a prognostic factor. Cancer. 1994;73:187–90.CrossRef
7.
Sturgis EM, Miller RH. Second primary malignancies in the head and neck cancer patient. Ann Otol Rhinol Laryngol. 1995;104:946–54.CrossRef
8.
Vermorken JB, Specenier P. Optimal treatment for recurrent/metastatic head and neck cancer. Ann Oncol. 2010;21(Suppl 7):vii252–vii61.CrossRef
9.
10.
11.
12.
13.
Metadaten
Titel
Treating head and neck cancer—A multidisciplinary effort
verfasst von
Gabriele Gamerith, MD
Assoc. Prof. PD Dr. Thorsten Fuereder
Publikationsdatum
01.12.2020
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 4/2020
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-020-00656-3

Weitere Artikel der Ausgabe 4/2020

Nutritional management during treatment for head and neck cancer

  • Open Access
  • short review

Molecular profiling—ready for clinical routine

  • editorial

Cytoreductive surgery and HIPEC in colorectal cancer—did we get hold of the wrong end of the stick?

  • Open Access
  • short review

Transoral robotic surgery in head and neck cancer

  • short review

Particle therapy in head and neck cancer—expanding therapeutic options

  • short review

Fertility preservation

  • editorial